Mechanisms of action of fluvoxamine for COVID-19: a historical review

The ongoing coronavirus disease 2019 (COVID-19) pandemic caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) accelerates the discovery of prophylactic and therapeutic drugs for persons infected with the virus. Drug repurposing for the COVID-19 pandemic has received parti...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Molecular psychiatry 2022-04, Vol.27 (4), p.1898-1907
Hauptverfasser:	Hashimoto, Yaeko, Suzuki, Takuji, Hashimoto, Kenji
Format:	Artikel
Sprache:	eng
Schlagworte:	631/154/53/2423 692/699/476/1414 82 Antidepressants Antidepressive Agents - pharmacology Autism Autism Spectrum Disorder - drug therapy Behavioral Sciences Biological Psychology Coronaviruses COVID-19 COVID-19 Drug Treatment Expert Review Fluvoxamine Fluvoxamine - pharmacology Fluvoxamine - therapeutic use Historical account Humans Intubation Medicine Medicine & Public Health Mental disorders Neurosciences Pandemics Pharmacotherapy Psychiatry SARS-CoV-2 Schizophrenia Serotonin transporter Severe acute respiratory syndrome coronavirus 2 Sphingomyelin phosphodiesterase
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!